The U.S. FDA has delayed a decision on AstraZeneca's breast cancer pill due to additional data requests, while Brazil approved its first generic version of Novo Nordisk's weight loss and diabetes drug.
Good morning! Today’s news brings updates from both the pharmaceutical industry in the United States and Brazil. The U.S. Food and Drug Administration (FDA) has extended the decision deadline for an experimental breast cancer pill from AstraZeneca to review additional data, reports. This delay follows a majority vote by an FDA advisory panel in April against the drug when used in combination with another therapy known as CDK4/6 inhibitor. The concern was over the design of a key late-stage trial rather than its safety or efficacy.
AstraZeneca has submitted new analyses to support its new drug application, including data on longer-term outcomes that will be presented at a conference on June 2. The company's camizestrant pill is targeted at patients with specific mutations in their breast cancer tumors.
Meanwhile, Brazil made history by approving the country’s first generic version of Novo Nordisk’s Ozempic shot. This approval opens the door to cheaper competition in one of the world’s fastest-growing markets for weight loss and diabetes drugs. EMS, a Brazilian pharmaceutical company, was cleared to sell its copycat drug, Ozivy, which will be priced 30% less than Ozempic. EMS plans to launch the drug within 30 days and expects initial sales of about 1.2 million units in the first year.
This approval marks a significant milestone for Brazil’s pharmaceutical industry as local companies aim to enter the booming market for GLP-1 medicines, which include Ozempic. The move is expected to significantly impact pricing and accessibility in this growing sector.
Stay informed with for more updates on these developments and other key stories in healthcare.
